Editorial-Orientierung von MedAPI — kein Bestandteil der Kodieranweisung.
C15 covers primary malignant neoplasms arising in the esophagus. Tumors are described by esophageal third—upper, middle, or lower—or as overlapping sites when a single tumor spans contiguous regions and the point of origin cannot be determined, or unspecified when the segment is not documented. Clinical reports may describe cervical, thoracic, or abdominal esophagus; these descriptors map onto the upper/middle/lower third subdivisions used in ICD-10-CM rather than forming separate subcategories.
Common Histologies
- Squamous cell carcinoma: More common in the proximal and middle esophagus; associated with tobacco use, alcohol exposure, and certain dietary or environmental factors.
- Adenocarcinoma: Usually arises in the distal esophagus, often in association with Barrett esophagus and chronic gastroesophageal reflux.
- Less common tumors include neuroendocrine carcinoma, adenosquamous carcinoma, and other rare epithelial malignancies.
Tumors involving the gastroesophageal junction require careful determination of the primary site. Tumors centered at the cardia/esophagogastric junction may fall under the gastric family (C16.0) rather than C15, so documentation of the epicenter matters.
Common Symptoms
- Progressive dysphagia, often initially to solids and later to liquids (R13.10)
- Unintentional weight loss (R63.4)
- Odynophagia or retrosternal discomfort (R07.0)
- Regurgitation (R11.10), aspiration (T17.910A), or persistent cough (R05.3)
- Hoarseness from recurrent laryngeal nerve involvement (R49.0)
- Iron-deficiency anemia or gastrointestinal bleeding (D50.0)
- Malnutrition in advanced disease (E46)
Diagnosis
Upper endoscopy with biopsy establishes the diagnosis and histology. Staging evaluation commonly includes contrast-enhanced CT of the chest and abdomen, and often the pelvis; FDG-PET/CT may help identify occult nodal or distant disease. Endoscopic ultrasound can assess depth of invasion and regional lymph nodes when technically feasible. Bronchoscopy may be appropriate for proximal or middle esophageal tumors when airway invasion is suspected.
Staging
Esophageal cancer is staged using the TNM system:
- T: Depth of tumor invasion and involvement of adjacent structures
- N: Regional lymph-node involvement
- M: Distant metastasis
Histologic type, tumor location, and treatment pathway may affect stage grouping and prognosis. Common metastatic sites include the liver, lungs, distant lymph nodes, bone, and adrenal glands.
Molecular Markers
For advanced or recurrent disease—particularly adenocarcinoma—testing may include:
- HER2 expression or amplification
- PD-L1 expression, commonly reported as a combined positive score
- Mismatch-repair deficiency or microsatellite instability
- Selected broader genomic testing for rare actionable alterations
Testing strategy depends on histology, stage, available tissue, and contemplated systemic therapy.
Common Treatments
Treatment is individualized through multidisciplinary assessment:
- Very early superficial disease: Endoscopic resection, sometimes followed by ablative therapy.
- Resectable localized disease: Esophagectomy with regional lymphadenectomy, often combined with neoadjuvant chemoradiation or perioperative chemotherapy.
- Proximal (cervical) esophageal tumors and selected squamous cell carcinomas: Definitive chemoradiation may be favored to preserve function or avoid highly morbid surgery.
- Unresectable, recurrent, or metastatic disease: Systemic chemotherapy, immunotherapy, HER2-directed therapy when indicated, or other biomarker-directed treatment.
- Supportive and palliative care: Nutritional support, swallowing interventions, endoscopic stenting, radiation, pain management, and management of aspiration or fistula risk.
Scope Note
C15 identifies a primary malignant neoplasm of the esophagus and distinguishes upper, middle, and lower third when documented, with separate overlapping-site and unspecified-site options. It does not by itself encode histologic subtype, TNM stage, grade, molecular profile, treatment status, or recurrence. Overlapping-site coding applies when one tumor spans contiguous esophageal regions and its point of origin cannot be determined; unspecified-site coding applies when the esophageal segment is not documented. Metastases to the esophagus are not primary C15 disease, and distant metastases from an esophageal primary require separate secondary malignant neoplasm codes. Associated alcohol abuse or dependence may require an additional F10.- code when documented, consistent with the classification note.